IP Library › Granted Patent US 12,410,193
Granted Patent B2
US 12,410,193 · App. 18/629,313 · Granted Sep 9, 2025

Bicyclic heterocyclyl derivatives as IRAK4 inhibitors

Inventors: Venkateshwar Rao Gummadi (Bangalore, IN); Susanta Samajdar (Bangalore, IN)
Assignee: Aurigene Oncology Limited
C07D513/04C07D498/04C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,193
App. No.
18/629,313
Granted
Sep 9, 2025
Kind
B2
Abstract

The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X 1 , X 2 , X 3 , R 1 , R 3 , ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salts or stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical compositions comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Claims (10)

1. A compound selected from

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is

3. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of

4. The compound of claim 1 , wherein the compound is

5. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of

6. The compound of claim 1 , wherein the compound is

7. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of

8. The compound of claim 1 , wherein the compound is

9. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2024
From: GUMMADI, VENKATESHWAR RAO; SAMAJDAR, SUSANTA
To: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
Reel/Frame 067433/0289 →
CHANGE OF NAME Recorded May 16, 2024
From: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
To: AURIGENE ONCOLOGY LIMITED
Reel/Frame 067433/0309 →
Priority Claims (2)
IN 158/CHE/2014 · Jan 13, 2014 · national
IN 3000/CHE/2014 · Jun 20, 2014 · national
Continuity (7)
Continuation 18141008 · Apr 28, 2023
Continuation 17245611 · Apr 30, 2021
Continuation 16795394 · Feb 19, 2020
Continuation 16054512 · Aug 3, 2018
Continuation 15667173 · Aug 2, 2017
Continuation 15111000
Related Publication 20240294547A1 · Sep 5, 2024
References Cited (283)
US 5494911A · Bartlett et al. · 1996 [cited by applicant]
US 7338950B2 · Kelly et al. · 2008 [cited by applicant]
US 9732095B2 · Gummadi et al. · 2017 [cited by applicant]
US 9855273B2 · Starczynowski et al. · 2018 [cited by applicant]
US 10047104B2 · Gummadi et al. · 2018 [cited by applicant]
US 10160753B2 · Gummadi et al. · 2018 [cited by applicant]
US 10640517B2 · Gummadi et al. · 2020 [cited by applicant]
US 10758518B2 · Booher · 2020 [cited by applicant]
US 10995100B2 · Gummadi et al. · 2021 [cited by applicant]
US 11419875B2 · Gummadi et al. · 2022 [cited by applicant]
US 11691987B2 · Gummadi et al. · 2023 [cited by applicant]
US 11981685B2 · Gummadi et al. · 2024 [cited by applicant]
US 12178821B2 · von Roemeling et al. · 2024 [cited by applicant]
US 20050192293A1 · Kelly et al. · 2005 [cited by applicant]
US 20060014747A1 · Krueger et al. · 2006 [cited by applicant]
US 20060160861A1 · Bohlmann et al. · 2006 [cited by applicant]
US 20090069288A1 · Breinlinger et al. · 2009 [cited by applicant]
US 20100160388A1 · Brotherton-Pleiss et al. · 2010 [cited by applicant]
US 20100210619A1 · Bombrun et al. · 2010 [cited by applicant]
US 20110224137A1 · Ting et al. · 2011 [cited by applicant]
US 20120015962A1 · Arora et al. · 2012 [cited by applicant]
US 20120053345A1 · Ericson et al. · 2012 [cited by applicant]
US 20130035326A1 · Abraham et al. · 2013 [cited by applicant]
US 20150094315A1 · Choi et al. · 2015 [cited by applicant]
US 20160326151A1 · Gummadi et al. · 2016 [cited by applicant]
US 20170152263A1 · Gummadi et al. · 2017 [cited by applicant]
US 20180022758A1 · Gummadi et al. · 2018 [cited by applicant]
US 20180201609A1 · Gummadi et al. · 2018 [cited by applicant]
US 20180208605A1 · Gummadi et al. · 2018 [cited by applicant]
US 20180289685A1 · Bothe et al. · 2018 [cited by applicant]
US 20200069668A1 · Lannutti et al. · 2020 [cited by applicant]
US 20200190112A1 · Gummadi et al. · 2020 [cited by applicant]
US 20210290628A1 · Gummadi et al. · 2021 [cited by applicant]
US 20220056046A1 · Gummadi et al. · 2022 [cited by applicant]
US 20220331330A1 · von Roemeling et al. · 2022 [cited by applicant]
US 20220339161A1 · Gummadi et al. · 2022 [cited by applicant]
US 20230310444A1 · von Roemeling et al. · 2023 [cited by applicant]
US 20230331740A1 · Gummadi et al. · 2023 [cited by applicant]
US 20230414582A1 · von Roemeling et al. · 2023 [cited by applicant]
US 20250082644A1 · von Roemeling et al. · 2025 [cited by applicant]
CN 103608017A · 2014 [cited by applicant]
EP 1627869A1 · 2006 [cited by applicant]
GB 2406856A · 2005 [cited by applicant]
JP 2008239617A · 2008 [cited by applicant]
JP 2013531018A · 2013 [cited by applicant]
KR 20130128693A · 2013 [cited by applicant]
WO WO2004007457A2 · 2004 [cited by applicant]
WO WO2004007458A1 · 2004 [cited by applicant]
WO WO2004098518A2 · 2004 [cited by applicant]
WO WO2004103954A1 · 2004 [cited by applicant]
WO WO2004108133A2 · 2004 [cited by applicant]
WO WO2005032493A2 · 2005 [cited by applicant]
WO WO2005107460A1 · 2005 [cited by applicant]
WO WO2006048249A1 · 2006 [cited by applicant]
WO WO2006053227A2 · 2006 [cited by applicant]
WO WO2006066173A2 · 2006 [cited by applicant]
WO WO2006066174A1 · 2006 [cited by applicant]
WO WO2006066795A1 · 2006 [cited by applicant]
WO WO2007058626A1 · 2007 [cited by applicant]
WO WO2007095124A2 · 2007 [cited by applicant]
WO WO2007112914A2 · 2007 [cited by applicant]
WO WO2007117465A2 · 2007 [cited by applicant]
WO WO2007121154A2 · 2007 [cited by applicant]
WO WO2008030579A2 · 2008 [cited by applicant]
WO WO2008030584A2 · 2008 [cited by applicant]
WO WO2008061109A2 · 2008 [cited by applicant]
WO WO2008073825A1 · 2008 [cited by applicant]
WO WO2008156614A2 · 2008 [cited by applicant]
WO WO2009012312A1 · 2009 [cited by applicant]
WO WO2009019167A1 · 2009 [cited by applicant]
WO WO2009102468A1 · 2009 [cited by applicant]
WO WO2010008847A2 · 2010 [cited by applicant]
WO WO2010071819A1 · 2010 [cited by applicant]
WO WO2011046954A1 · 2011 [cited by applicant]
WO WO2011133750A1 · 2011 [cited by applicant]
WO WO2011137219A1 · 2011 [cited by applicant]
WO WO2011163640A1 · 2011 [cited by applicant]
WO WO2012007375A1 · 2012 [cited by applicant]
WO WO2012068546A1 · 2012 [cited by applicant]
WO WO2012084704A1 · 2012 [cited by applicant]
WO WO2012142125A2 · 2012 [cited by applicant]
WO WO2013042137A1 · 2013 [cited by applicant]
WO WO2013056070A2 · 2013 [cited by applicant]
WO WO2013059587A1 · 2013 [cited by applicant]
WO WO2013068458A1 · 2013 [cited by applicant]
WO WO2014003483A1 · 2014 [cited by applicant]
WO WO2014011902A1 · 2014 [cited by applicant]
WO WO2014070979A1 · 2014 [cited by applicant]
WO WO2014190163A2 · 2014 [cited by applicant]
WO WO2015038503A1 · 2015 [cited by applicant]
WO WO2015091426A1 · 2015 [cited by applicant]
WO WO2015104662A1 · 2015 [cited by applicant]
WO WO2015104688A1 · 2015 [cited by applicant]
WO WO2015119998A1 · 2015 [cited by applicant]
WO WO2015193846A1 · 2015 [cited by applicant]
WO WO2016083433A1 · 2016 [cited by applicant]
WO WO2017009798A1 · 2017 [cited by applicant]
WO WO2017009806A1 · 2017 [cited by applicant]
WO WO2017023941A1 · 2017 [cited by applicant]
WO WO2018081738A1 · 2018 [cited by applicant]
WO WO2018178947A2 · 2018 [cited by applicant]
WO WO2019089580A1 · 2019 [cited by applicant]
WO WO2020113233A1 · 2020 [cited by applicant]
WO WO2020264499A1 · 2020 [cited by applicant]
WO WO2022031330A1 · 2022 [cited by applicant]
WO WO2022108996A1 · 2022 [cited by applicant]
WO WO2022216379A1 · 2022 [cited by applicant]
WO WO2023220227A1 · 2023 [cited by applicant]
WO WO2024249837A1 · 2024 [cited by applicant]
WO WO2024249839A1 · 2024 [cited by applicant]
D'Angelo, “Targeting IRAK4 as Novel Therapy in Primary CNS Lymphoma,” University of Nebraska Medical Center, Published Aug. 7, 2024: 13 slides. [cited by applicant]
Extended European Search Report for EP Application No. 21895491.5 dated Aug. 27, 2024. [cited by applicant]
Extended European Search Report for EP Application No. 21852519.4 dated Aug. 1, 2024. [cited by applicant]
Giménez et al., “Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia.” Leukemia 34.1 (2020): 100-114. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US24/31970 dated Jul. 18, 2024. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US24/31972 dated Aug. 26, 2024. [cited by applicant]
Wiese et al., “Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis.” Expert opinion on investigational drugs 29.5 (2020): 475-482. [cited by applicant]
Abu-Duhier et al., “FLT3 internal tandem duplication mutations in adult acute myeloid leukemia define a high-risk group,” British Journal of Haematology, 111: 190-195 (2000). [cited by applicant]
Alder, C. M. et al., “Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy”, [cited by applicant]
Anonymous, “Chronic myelomonocytic leukaemia”, Leukaemia Foundation, Retrieved from the Internet: https://www.leukaemia.org.au/blood-cancer/myelodysplastic-syndromes/chronic-myelomonocytic-leukaemia/, pp. 1-2 (2019). [cited by applicant]
Bains et al., “FLT3 and NPM1 Mutations in Myelodysplastic Syndromes: Frequency and Potential Value for Predicting Progression to Acute Myeloid Leukemia,” American Journal of Clinical Pathology, 135(1): 62-69 (2011). [cited by applicant]
Balasubramanian et al., “Abstract 3646: Novel IRAK-4 inhibitors exhibit highly potent anti-proliferative activity in DLBCL cell lines with activating MYD88 L265P mutation,” Cancer Research, 75(15 Suppl):Abstract 3646 (2… [cited by applicant]
Bennett et al., “IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies.” Current Opinion in Hematology, vol. 29, No. 1, p. 8 (2022). [cited by applicant]
Bhagat et al., “Abstract 2570: IMO-8400, a selective antagonist of TLRs 7, 8 and 9, inhibits MYD88 L265P mutation-driven signaling and cell survival: A potential novel approach for treatment of B-cell lymphomas harborin… [cited by applicant]
Blackmon et al., “Test then erase? Current status and future opportunities for Measurable Residual Disease testing in Acute Myeloid Leukemia”, Acta Haematologica, pp. 1-14, (2023). [cited by applicant]
Booher et al., “Combination of IRAK4 (CA-4948) and BTK (Vecabrutinib) Inhibitors Show Superior Efficacy in Preclinical Models of Abc Dlbcl Tumors Containing MYD88-L265P Mutations,” Hematological Oncology, 37(S2): 512- 5… [cited by applicant]
Booher et al., “Combination of IRAK4 Inhibitor CA-4948 with BCL2 Inhibitor Venetoclax Induces Tumor Regression in an ABC-DLBCL Xenograft Model”, Blood, 130(1): 1534, (2017). [cited by applicant]
Booher et al., “Preclinical activity of IRAK4 kinase inhibitor CA-4948 alone or in combination with targeted therapies and preliminary phase 1 clinical results in non-Hodgkin lymphoma.” Blood, vol. 132, No. 4168 (2018). [cited by applicant]
Burguera et al., “Trial in Progress: A Phase 1b Single-Arm, Open-Label Study of Emavusertib (CA-4948) in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurabl… [cited by applicant]
Chen et al., “Design and Synthesis of a Series of Non-Peptide High-Affinity Human Corticotropin-Releasing Factor1 Receptor Antagonists,” J Med Chem, 39:4358-4360 (1996). [cited by applicant]
Chen et al., “Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma,” Eur J Med Chem, 190: 11209 (33 pages) (2020). [cited by applicant]
Choudhary et al., “Abstract 127: Efficacy of novel IRAK4 inhibitor CA4948 in AML and MDS,” Proceedings of the American Association for Cancer Research Annual Meeting 2017; Apr. 1-5, 2017; Washington, DC. Philadelphia (P… [cited by applicant]
Choudhary et al., “SF3B1 Mutations Induce Oncogenetic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML,” Blood, 134(Supplement 1): 4224 (5 pages) (2019). [cited by applicant]
Clinical study NCT04278768 (V3), “An Open Label Dose Escalation Trial of CA-4948 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome,” Clinical Trials (6 pages) (2020). [cited by applicant]
Curis Corporate Presentation, NASDAQ:CRIS, Jul. 1, 2020. [cited by applicant]
Curis Inc. First Quarter 2020 Financial Results, May 12, 2020. [cited by applicant]
Curis, “Dec. 2020 Key Opinion Leader Event,” (22 pages) (2020). [cited by applicant]
Dadabayev, “DAKA nVision+ System, Peroxidase,” Biocompare, (7 pages) (2004). [cited by applicant]
Das et al., “Effects of Positional and Geometrical isomerism on the Biological Activity of Some Novel Oxazolidinones,” Bioorg Med Chem Lett, 15:337-343 (2005). [cited by applicant]
Das et al., “Impact Analysis of SARS-COV2 on Signaling Pathways During COVID19 Pathogenesis Using Codon Usage Assisted Host-Viral Protein Interactions,” BioRxiv, (27 pages) (2020). [cited by applicant]
Davids et al., “Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,” J Clin Oncol, 35(8): 826-833 (2015). [cited by applicant]
De la Fuente et al. “A phase 1 single-arm, open-label study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in patients (pts) with acute myeloid leukemia (AML) in complete response (CR) with meas… [cited by applicant]
Doonan et al., “CA-4948 for the treatment of melanoma brain metastasis,” Central Nervous System Tumors: 1 page (Published Apr. 16, 2022). [cited by applicant]
Ex Parte Cao, Decision rendered by the Board of Patent Appeals and Interferences in U.S. Appl. No. 10/696,862, filed Sep. 21, 2011. [cited by applicant]
Extended European Search Report for EP Application No. 18777745.3 mailed Jul. 27, 2020. [cited by applicant]
Extended European Search Report for EP Application No. 18873778.7 dated Jul. 23, 2021. [cited by applicant]
Extended European Search Report for EP Application No. 20211096.1 dated Feb. 12, 2021. [cited by applicant]
Extended European Search Report for EP Application No. 23173240.5 dated Nov. 11, 2023. [cited by applicant]
Extended European Search Report for EP Application No. 23214923.7 dated Jun. 5, 2024. [cited by applicant]
Extended European Search Report for EP Application No. EP 16823968, mailed Dec. 10, 2018. [cited by applicant]
Extended European Search Report for EP Application No. EP 16823970 issued Jun. 25, 2019. [cited by applicant]
Extended European Search Report for EP Application No. EP 18190333 issued Mar. 13, 2019. [cited by applicant]
Extended European Search Report issued by the European Patent Office in corresponding Application No. PCT/IB2015054620 dated Jan. 16, 2018. [cited by applicant]
Extended European Search Report issued by the European Patent Office in corresponding International Application No. PCT/IB2015/050217, dated May 2, 2017. [cited by applicant]
Faison, “Curis: Differentiated IRAK4 Inhibitor To Drive Value Creation in the Near Term,” Seeking Alpha, Mar. 1, 2021. [cited by applicant]
Fathi et al., “Treatment of FLT3-ITD acute myeloid leukemia,” Am. J. Blood. Res., 1(2): 175-189 (2011). [cited by applicant]
Gao et al., “Inhibition of IL-1 Receptor-Associated Kinase 1 Decreases Murine Acute Graft-versus-Host Disease While Preserving the Graft-versus-Lymphoma Effect.” Transplantation and Cellular Therapy, vol. 28, No. 3, pp.… [cited by applicant]
Garcia-Manero et al., “2863 A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous … [cited by applicant]
Garcia-Manero et al., “A Phase 1, Dose Escalation Trial With Novel Oral IRAK4 Inhibitor CA-4948 In Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome—Interim Report,” Curis Inc. Presentation published … [cited by applicant]
Garcia-Manero., “Spliceosome Mutations, IRAK4 and CA-4948 in MDS and AML,” Curis Inc. Presentation published Apr. 24, 2021 (22 pages). [cited by applicant]
Genung et al., “Chapter Four—Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4),” Progress in Medicinal Chemistry, 56: 117-163 (2017). [cited by applicant]
Gerecitano et al., “A Phase 1 Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma,” Blood, 126(23):254 (2015). [cited by applicant]
Golub et al., “Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring,” Science, 286: 531-537 (1999). [cited by applicant]
Grommes et al., “Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) patients.” American Society of Clinical Oncology. (2024). [cited by applicant]
Gupta et al., “Interleukin-1-receptor kinase 4 inhibition: achieving immunomodulatory synergy to mitigate the impact of COVID-19.” Frontiers in Immunology, vol. 12, No. 693085. (2021). [cited by applicant]
Huang et al., “Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway,” Cell Signalling, 22(9): 1282-90 (2010). [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2021/059668 dated Feb. 24, 2022. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2022/017902 dated Aug. 3, 2022. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2023/021812 dated Aug. 6, 2023. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2015/050119 dated Mar. 19, 2015. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2015/050217 dated Apr. 29, 2015. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2015/054620 dated Oct. 19, 2015. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2016/054203 mailed Sep. 23, 2016. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2016/054229 mailed Nov. 15, 2016. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US/2018/058194 mailed Feb. 3, 2019. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/030192 mailed Jun. 25, 2021. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/059668 mailed Feb. 24, 2022. [cited by applicant]
Iqbal et al., “Preliminary safety and efficacy data on two patients with relapsed/refractory CNS lymphoma treated with emavusertib (CA-4948) and ibrutinib combination: a subset analysis of TakeAim Lymphoma trial,” CURIS… [cited by applicant]
Issue Notice for U.S. Appl. No. 17/245,611 dated Jun. 14, 23. [cited by applicant]
Issue Notification for U.S. Appl. No. 16/498,866 dated Aug. 3, 2022. [cited by applicant]
Kelly et al., “Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy,” J Exp Med, 212(13):2189-2201 (2015). [cited by applicant]
Knapper et al., “An evaluation of the tyrosine kinase inhibitor pacritinib in patients with relapsed FLT3-mutated acute myeloid leukaemia (the UK NCRI AML17 study),” Haematologica, 101(1): 40 (2016). [cited by applicant]
Lala at al., “Role of nitric oxide in tumor progression: Lessons from experimental tumors,” Cancer and Metastasis Reviews, 17(1):91-106 (1998). [cited by applicant]
Landgren et al., “MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenstroöm's Macroglobulinemia,” Leukemia, 28(9): 1799-1803 (2014). [cited by applicant]
Lane, “IRAK4 inhibition in AML, MDS and B cell Cancers,” Curis Presentation Published Sep. 29, 2021. [cited by applicant]
Lange et al., “Preclinical evaluation of a novel interleukin-I receptor-associated kinase 4 (IRAK.4) inhibitor in combination with PBK inhibitor copanlisib or BTK inhibitors in ABC-DLBCL” [abstract]. In: Proceedings of … [cited by applicant]
Li et al., “Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies,” Journal of Clinical Investigation, 125(3): 1081-1097 (2015). [cited by applicant]
Li et al., “Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1,” Leukemia, 29:1702-1712 (2015). [cited by applicant]
Martell, “Discovery and Development of IRAK4 Inhibitor Emavusertib”, Curis Presentation: 36 pages (Sep. 29, 2022). [cited by applicant]
Martell, “Emavusertib,” Curis Presentation: 15 pages (Oct. 7, 2022). [cited by applicant]
McElroy, “Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018).” Expert opinion on therapeutic patents, vol. 29, No. 4, pp. 243-259.(2019). [cited by applicant]
Metzeler et al., “ASH Poster #4077: Molecular characterization of clinical response in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome patients treated with single agent emavusertib,” P… [cited by applicant]
Metzeler et al., “Molecular characterization of clinical response in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome patients treated with single agent emavusertib,” American Society of… [cited by applicant]
Metzeler et al., “Molecular characterization of clinical response in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome patients treated with single agent emavusertib,” Curis Inc. Presenta… [cited by applicant]
Metzeler et al., “Predictive biomarkers of response to the IRAK4/FLT3 inhibitor emavusertib in hematological malignancies.” American Society of Clinical Oncology. (2024). [cited by applicant]
Nowakowski et al., “# 2945: A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a novel IRAK4 inhibitor CA-4948 in combination with ibrutinib, in Patients with… [cited by applicant]
Nowakowski et al., “703 Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study,” Abstract, AS… [cited by applicant]
Partial Search Report and Written Opinion for EP Patent Application No. EP16823970, mailed Mar. 19, 2019. [cited by applicant]
Rao et al., “Abstract C191: Efficacy of novel IRAK4 inhibitors in ABC-DLBCL and AML models,” Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; Nov. 5-9, 2015; Boston,… [cited by applicant]
Rao Gummadi et al., “Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies,” ACS Medicinal Chemistry Letters: 8 pages (2020). [cited by applicant]
Rhyasen., “IRAK family kinases as therapeutic targets for Myelodysplastic Syndrome and Acute Myeloid Leukemia” University of Cincinnati: 132 pages (2014). [cited by applicant]
Santa Cruz Biotechnology, “p-NFkB p50 (A-8): sc-271908,” (1 page) (2012). [cited by applicant]
STN Registry database entry: [online] 2011, CAS RN 1301085-08-4 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2011, CAS RN 1421459-19-9 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2011, CAS RN 1421491-68-0 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2011, CAS RN 1421497-05-3 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1178067-91-8 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1184469-61-1 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1223638-97-8 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1252319-44-0 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1274105-18-8 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1282974-67-7 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1333957-90-6 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1346410-97-6 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1367793-38-1 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1368333-88-3 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1369195-81-2 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1381262-66-3 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1381667-74-0 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1396710-33-0 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1405289-53-3 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1414842-47-9 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1414842-48-0 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1421504-43-9 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1421508-39-5 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1423498-44-5 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1522249-43-9 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1548563-20-7 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1570255-99-0 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: [online] 2014, CAS RN 1575185-05-5 (Search date: Feb. 9, 2019). [cited by applicant]
STN Registry database entry: CAS RN 1181327-83-2 (Entered STN: Sep. 8, 2009). (Year: 2009). [cited by applicant]
STN Registry database entry: CAS RN 1301085-08-4 (Entered STN: May 26, 2011). (Year: 2011). [cited by applicant]
Sun et al., “Synthesis, in Vitro Evaluation and Cocrystal Structure of 4-Oxo-[1]benzopyrano[4,3-c]pyrazole Cryptosporidium parvum Inosine 5′-Monophosphate Dehydrogenase (CpIMPDH) Inhibitors,” J Med Chem, 57:10544-10550 … [cited by applicant]
Takami et al., “Design and synthesis of Rho kinase inhibitors (I),” Bioorg Med Chem, 12:2115-2137 (2004). [cited by applicant]
Ugolkov et al., “Identification of NF-kappaB phospho-p50 as a predictive biomarker for IRAK4 inhibitor CA-4948 in patients with Non-Hodgkin's lymphoma,” American Associates for Cancer Research, published on Nov. 19, 202… [cited by applicant]
Ugolkov et al., “Identification of NF-kB phospho-p50 as a potential predictive biomarker for IRAK4 inhibitor CA-4948 in patients with Non-Hodgkin's lymphoma,” AACR Annual Meeting 2021, Poster No. 385. [cited by applicant]
Viatour et al., “Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation,” Trends Biochem Sci, 30(1): 43-52 (2005). [cited by applicant]
Von Roemeling et al., “Clinical Activity of IRAK4 Inhibitor, Emavusertib (CA-4948),” Curis Presentation published Oct. 29, 2022 (15 pages). [cited by applicant]
Von Roemeling et al., “The IRAK4 inhibitor CA-4948 demonstrates antitumor activity in a preclinical model of CNS lymphoma,” Molecular Targets and Cancer Therapeutics, Curis Presentation published Oct. 7, 2021 (9 pages). [cited by applicant]
Von Roemeling, “IRAK-4 as a therapeutic target in primary CNS lymphoma”, University of Florida, Curis, Presentation 28 slides (2022). [cited by applicant]
Wang et al., “Crystal Structures of IRAK-4 Kinase in Complex with Inhibitors: A Serine/Threonine Kinase with Tyrosine as a Gatekeeper,” Structure 14, 1835-1844 (2006). [cited by applicant]
Winer et al., “Preliminary Safety, Efficacy and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Patients with FLT3 Mutation (FLT3m) ” American Society of Cli… [cited by applicant]
Younes et al., “Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information,” Blood, 134(1): 5327 (3 pages) (2019). [cited by applicant]
Yu et al., “Targeting NF-KB pathway for the therapy of diseases: mechanism and clinical study,” Sig Transduct Target Ther, 5(209) (23 pages) (2020). [cited by applicant]
Zhang et al.“Canonical NF-kB Signalling Is a Potential Target in FLT3/ITD AML.” Blood, vol. 120, No. 21, p. 2447 (2012). [cited by applicant]
Zhang et al., “Design, synthesis and evaluation of bicyclic benzamides as novel 5-HT1F receptor agonists,” Bioorg Med Chem Lett, 14(24):6011-6016 (2004). [cited by applicant]
Zhang et al., “Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer,” Journal of Hematology & Oncology, 15: Article 70 pp. 1-5 (2022). [cited by applicant]
Zhang et al., “Targeting NF-KB pathway for the therapy of diseases: mechanism and clinical study,” Sig Transduct Target Ther 5(209): 23 pages (2020). [cited by applicant]
Bai et al., “The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases,” European Journal of Medicinal Chemistry 258 (2023): 15606. [cited by applicant]
Blood Cancer UK, “Relapse and refractory AML treatments,” Retrieved on Nov. 15, 24 from: https://bloodcancer.org.uk/understanding-blood-cancer/leukaemia/acute-myeloid-leukaemia/aml-treatment/relapse-refractory/. [cited by applicant]
Extended European Search Report for EP Application No. 24168755.7 dated Oct. 10, 2024. [cited by applicant]
Grommes et al., “Analysis of genetic mutation profile and CNS pharmacokinetics in relapsed/refractory primary CNS lymphoma patients responding to novel emavusertib (IRAK4i) and BTKi combination ,” Abstract. Jan. 27, 202… [cited by applicant]
Guidetti et al., “Targeting IRAK4 with emavusertib in lymphoma models with secondary resistance to PI3K and BTK inhibitors.” Journal of Clinical Medicine 12 (2023): 399. [cited by applicant]
Pleyer et al., “Azacitidine for Front-Line Therapy of Patients with AML,” International Journal of Molecular Sciences 18 (2017): 415 (18 pages). [cited by applicant]
Smith et al., “Alternative Splice Variants of IRAK4 That Activate Innate Immune Signaling Are Associated with U2AF1 Mutations in Myelodysplastic Syndrome and Acute Myeloid Leukemia,” Blood 128.22 (2016): 1531. Abstract. [cited by applicant]
U.S. Appl. No. 15/110,309, Granted. [cited by applicant]
U.S. Appl. No. 15/111,000, Granted. [cited by applicant]
U.S. Appl. No. 15/667,173, Granted. [cited by applicant]
U.S. Appl. No. 16/054,512, Granted. [cited by applicant]
U.S. Appl. No. 16/795,394, Granted. [cited by applicant]
U.S. Appl. No. 17/245,611, Granted. [cited by applicant]
U.S. Appl. No. 18/141,008, Granted. [cited by applicant]
U.S. Appl. No. 16/498,866, Granted. [cited by applicant]
U.S. Appl. No. 17/853,299, Pending. [cited by applicant]
U.S. Appl. No. 16/176,940, Granted. [cited by applicant]
U.S. Appl. No. 18/019,400, Pending. [cited by applicant]
U.S. Appl. No. 18/037,697, Pending. [cited by applicant]
U.S. Appl. No. 17/680,995, Granted. [cited by applicant]
U.S. Appl. No. 18/953,879, Pending. [cited by applicant]
U.S. Appl. No. 18/864,799, Pending. [cited by applicant]
Arranz et al., “Interleukin-1 [beta] as emerging therapeutic target in hematological malignancies and potentially in their complications.” Blood Reviews 31(5) (2017): 306-317. [cited by applicant]
Chen et al., “Immediate early response 3 gene promotes aggressive progression and autophagy of AML by negatively regulating AKT/mTOR.” Translational Oncology 35 (2023): 101711. [cited by applicant]
Clinical Trial NCT05187182, “CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/− Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer,” last update posted Jan. 15, 2025. Available at: https://clinicalt… [cited by applicant]
Clinical Trial NCT05669352, “A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases,” last update posted Apr. 4, 2025. Availab… [cited by applicant]
Clinical Trial NCT06439836, “Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy,” last update posted Mar. 10, 2025. Available at: https://c… [cited by applicant]
Day et al., “Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.” British Journal of Haematology 190(2) (2020): e80. [cited by applicant]
Doonan, “Novel oral IRAK-4 inhibition plus checkpoint inhibition in metastatic melanoma,” Hematology and Oncology 2022. Available at https://web.archive.org/web/20220703052454/https://discovery.education.med.ufl.edu/hem… [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US24/52925 dated Feb. 6, 2025. [cited by applicant]
Parrondo et al., “IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies.” Frontiers in Immunology 14 (2023): 1239082. [cited by applicant]
Supplementary European Search Report for EP Application No. 22785128.4 dated Jan. 27, 2025. [cited by applicant]
Ugolkov et al., “IRAK4 inhibitor CA-4948 potentiates antitumor effects of azacitidine and venetoclax in human acute myeloid leukemia”, Curis. EHA 2021, Jun. 9-17, 2021. [cited by applicant]
Ugolkov et al., “IRAK4 inhibitor CA-4948 potentiates antitumor effects of azacitidine and venetoclax in human acute myeloid leukemia”, HemaSphere, vol. 5, Suppl. 2, 26th Congress of the European Hematology Association, … [cited by applicant]
Zhang et al.,. “Constitutive IRAK4 activation underlies poor prognosis and chemoresistance in pancreatic ductal adenocarcinoma.” Clinical Cancer Research 23(7) (2017): 1748-1759. [cited by applicant]